Zelgen(SH:688266) 智通财经网·2025-11-18 07:57Core Viewpoint - ZG006, a tri-specific antibody developed by the company, has received approval for clinical trials in small cell lung cancer, marking a significant advancement in cancer treatment options [1][2]. Group 1: Drug Approval and Development - The company has received the Clinical Trial Approval Notice from the National Medical Products Administration (NMPA) for ZG006 in combination with PD-1/PD-L1 inhibitors and chemotherapy for small cell lung cancer [1]. - ZG006 has also been granted clinical trial permissions by the FDA in the United States and has been recognized as a breakthrough therapy by the NMPA [1]. Group 2: Mechanism of Action - ZG006 targets two different DLL3 epitopes and CD3, effectively bridging tumor cells and T cells to enhance T cell-mediated tumor cell killing [2]. - Preclinical studies have demonstrated significant tumor suppression in mouse models, with a notable proportion of tumors completely regressing, indicating ZG006's potent anti-tumor activity [2]. Group 3: Unique Positioning - ZG006 is the first-in-class tri-specific antibody targeting DLL3, with the potential to become a best-in-class molecule in its category [1].